Bluejay Diagnostics entered agreement with investors to exercise warrants at reduced price

From GlobeNewswire: 2025-04-07 17:21:00

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) has entered into an agreement with institutional investors to exercise existing warrants to purchase up to 1,085,106 shares of common stock at a reduced price of $3.42 per share, resulting in gross proceeds of approximately $3.7 million. In exchange, investors received new warrants to purchase the same number of shares at the same price, exercisable immediately and expiring in five years. The Company issued and sold the new warrants in reliance on exemptions from registration requirements. Aegis Capital Corp. acted as the exclusive financial advisor for the transaction.

Bluejay Diagnostics is a medical diagnostics company focused on improving patient outcomes with its Symphony System, a rapid testing system for sepsis triage. The company’s first product candidate, an IL-6 Test for sepsis, provides accurate results in approximately 20 minutes. This press release contains forward-looking statements about the completion of the transaction, intended use of proceeds, FDA submission plans, and more. The company advises not to place undue reliance on these statements, as actual results may differ due to known and unknown risks and uncertainties.



Read more at GlobeNewswire: Bluejay Diagnostics Announces Entry into Warrant Inducement